These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31898637)

  • 1. Identification of clinical and immunological factors associated with clinical relapse of pemphigus vulgaris in remission.
    Guliani A; De D; Handa S; Mahajan R; Sachdeva N; Radotra BD; Kishore K
    Indian J Dermatol Venereol Leprol; 2020; 86(3):233-239. PubMed ID: 31898637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission.
    Daneshpazhooh M; Zafarmand Sedigh V; Balighi K; Hosseini SH; Ramezani A; Kalantari MS; Ghandi N; Ghiasi M; Nikoo A; Chams-Davatchi C
    J Am Acad Dermatol; 2016 Jun; 74(6):1160-5. PubMed ID: 26896293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris.
    Daneshpazhooh M; Kamyab K; Kalantari MS; Balighi K; Naraghi ZS; Shamohammadi S; Mortazavizadeh SM; Ramezani A; Chams-Davatchi C
    Clin Exp Dermatol; 2014 Jan; 39(1):41-7. PubMed ID: 23782219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct immunofluorescence of plucked hair for evaluation of immunologic remission in pemphigus vulgaris.
    Daneshpazhooh M; Naraghi ZS; Ramezani A; Ghanadan A; Esmaili N; Chams-Davatchi C
    J Am Acad Dermatol; 2011 Dec; 65(6):e173-7. PubMed ID: 21696851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and serological predictors of relapse in pemphigus: a study of 143 patients.
    Genovese G; Maronese CA; Casazza G; Corti L; Venegoni L; Muratori S; Berti E; Fanoni D; Marzano AV
    Clin Exp Dermatol; 2022 Jan; 47(1):98-106. PubMed ID: 34288016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunological features of pemphigus relapse.
    Ujiie I; Ujiie H; Iwata H; Shimizu H
    Br J Dermatol; 2019 Jun; 180(6):1498-1505. PubMed ID: 30585310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
    Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orodigital pemphigus vulgaris: a pathogenic role of anti-desmoglein-3 autoantibodies in pemphigus paronychia?
    Laffitte E; Panizzon RG; Borradori L
    Dermatology; 2008; 217(4):337-9. PubMed ID: 18799879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Importance of Immunological Profile for Pemphigus Vulgaris in the Light of Necessity to Modify Compensation Theory.
    Öktem A; Hayran Y; Uysal Pİ; Atılan AU; Yalçın B
    Acta Dermatovenerol Croat; 2018 Jun; 26(2):100-104. PubMed ID: 29989864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Direct Immunofluorescence of Plucked Hair and Skin for Evaluation of Immunological Remission in Pemphigus.
    Rai R; Harikumar MV
    Indian Dermatol Online J; 2017; 8(5):319-322. PubMed ID: 28979862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of commercially available ELISA assays as a tool for monitoring and managing pemphigus patients: a prospective study.
    Bracke S; Speeckaert R; Van Geel N; De Bacquer D; Lambert J
    Eur J Dermatol; 2013; 23(1):33-9. PubMed ID: 23302186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission.
    Russo I; De Siena FP; Saponeri A; Alaibac M
    Medicine (Baltimore); 2017 Nov; 96(46):e8801. PubMed ID: 29145342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N; Bhol KC; Ahmed RA
    Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemphigus in remission: value of negative direct immunofluorescence in management.
    Ratnam KV; Pang BK
    J Am Acad Dermatol; 1994 Apr; 30(4):547-50. PubMed ID: 8157779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.